ArticleJournal of molecular medicine (Berlin, Germany)2016

Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways.

Wenbo Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.